Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
- Collaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal™ blood test
- Susan G. Komen Advocates in Science will provide patient perspective to inform design of research studies and strategies for personalized cancer care
The focus of the partnership will be to support the development of clinical utility data for Guardant Reveal™, a blood test for the detection of minimal residual disease (MRD) in patients with early-stage breast cancer. The test detects circulating tumor DNA (ctDNA) in the blood as a measurement of MRD, the presence of which indicates a high risk for disease recurrence.
A critical element of the partnership is the use of input from patient advocates to guide the research study design. These advocates, who serve as Susan G. Komen Advocates in Science, will provide a first-hand perspective of what matters most to patients with early-stage breast cancer in the development of research to find more effective approaches to their care.
“Susan G. Komen’s partnership with Guardant will help us achieve our goal of conquering deadly and aggressive breast cancers and saving lives by moving us towards personalized treatment through identifying which patients are at higher risk for recurrence,” said
“We’re excited to partner with
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20221221005074/en/
Guardant Health Contacts:
Investor Contact:
investors@guardanthealth.com
+1 657-254-5417
Media Contact:
press@guardanthealth.com
+1 215-910-2138
Susan G. Komen Contact:
askahan@komen.org
+1 972 701 2131
Source: